Overview

Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors

Status:
Not yet recruiting

Trial end date:
2026-03-01

Target enrollment:

Participant gender:

Summary

This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Synthekine

Treatments:

Pembrolizumab